StockData
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30

ARROWHEAD PHARMACEUTICALS, INC.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$57.23+1.33 (+2.38%)

Close on Oct 19, 2026

Market cap
$8.21B
P/E (TTM)
–
Dividend yield
–

ARROWHEAD PHARMACEUTICALS, INC. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Arrowhead Pharmaceuticals does not break out revenue by segment, region or product in the tagged data of its filings for this period type.